Breaking News
Close
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

Novartis AG (0QLR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
86.76 -1.30    -1.48%
27/05 - Closed. Currency in CHF ( Disclaimer )
  • Volume: 2,388,599
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 86.76 - 86.76
Type:  Equity
Market:  United Kingdom
ISIN:  CH0012005267 
SEDOL:  B10S3M3
Novartis 86.76 -1.30 -1.48%
IndustryPharmaceuticals
SectorHealthcare
Employees

110000

Equity Type

ORD

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Contact Information

Phone 41 61 324 1111
Fax 41 61 324 8001

Top Executives

Name Age Since Title
Joerg Reinhardt 66 1999 Independent Non-Executive Chairman
Daniel L. Vasella 69 1996 Honorary Chairman
William Thomas Winters 61 2013 Independent Non-Executive Director
Charles L. Sawyers 63 2013 Independent Non-Executive Director
Nancy C. Andrews 64 2015 Independent Non-Executive Director
Bridgette P. Heller 61 2020 Independent Non-Executive Director
François Adrianus van Houten 62 2017 Independent Non-Executive Director
Simon E. Moroney 63 2020 Independent Vice Chairman of the Board
Ana de Pro Gonzalo - 2022 Director
Daniel Hochstrasser - 2022 Independent Director
Andreas von Planta 67 2006 Independent Non-Executive Director
Ton Buechner 57 2016 Independent Non-Executive Director
Elizabeth Doherty 65 2016 Independent Non-Executive Director
Patrice Bula 66 2019 Lead Independent Director
Sidonie Golombowski-Daffner - - Chairperson & President of Advanced Accelerator Applications
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NOVN Comments

Write your thoughts about Novartis AG
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Lee Taylor
Lee Taylor Dec 01, 2021 10:39
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Novartis is trading at a value last seen in 2018; the funds released from a Sandoz divestment need to be directed towards further patient innovation from this Swiss Pharma major …
Lukas Bednall
Lukas Bednall Sep 28, 2021 15:36
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hi Guys, I have been invested in Novartis for 5 years and have closely followed the pharmaceutical industry for years. I have been very disappointed with the returns and am looking to transfer my portfolio into riskier assets. Upon research, I think I may have found an even better pharmaceutical company going by the name of SpectrumX. SpectrumX are leaders in patented shielded HOCL formulations that have numerous applications in medical/pharma fields. They have also undergone 2 clinical trials for Covid-19 treatment (apparently not factored into the company valuation.) To me this company seems to be on track for high growth after the IPO, however I may be getting lost in the hype. Would love to hear people's thoughts on the stock as I am keen to invest early.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Our Apps
DOWNLOAD APPApp store
Investing.com
© 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
  • Sign up for FREE and get:
  • Real-Time Alerts
  • Advanced Portfolio Features
  • Personalized Charts
  • Fully-Synced App
Continue with Google
or
Sign up with Email